Asset sale Announced
GSK acquisition of trispecific T cell-engager (TCE) asset
US$750m consideration
Announced Sep 2026
Advisers
trispecific T cell-engager (TCE) asset
Target
- Legal adviser
- Target
- trispecific T cell-engager (TCE) asset
- Acquirer
- GSK
- Seller
- Chimagen Biosciences
- Target based in
- China (unverified)
- Buyer based in
- United Kingdom
- Seller based in
- China (unverified)
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
Similar deals
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Eli Lilly and Company acquisition of CrossBridge Bio Apr 2026 · US$300m · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
